AbbVie Inc. (ABBV) Form 10-Q — Aug 3, 2026
AbbVie reported worldwide net revenues of $32.0 billion for the six months ended June 30, 2026, an increase of 11.2% on a reported basis. This growth was primarily driven by strong performance in Immunology, with Skyrizi revenues increasing 26.3% and Rinvoq increasing 24.0%, which successfully offset the 38.2% decline in Humira revenues due to biosimilar competition. Diluted earnings per share attributable to AbbVie Inc. rose to $2.42 from $1.24 in the prior year period.
Key figures
- Eps
- 2.42
- Revenue
- 31992
- Net Income
- 4308
- Cash Position
- 6569
- Deal Value Usd
- 10900
- Revenue Growth
- 11.2%
- Operating Cash Flow
- 7265
- Humira Revenue Growth
- -38.2%
Price after filing
Close on the filing date to close N calendar days later (from $257.41). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.